We designed ASOs complementary to either teloG or teloC dilncRNAs, called antiteloG and antiteloC ASO respectively, and control non-telomeric ASO, and determined their impact on HeLa, BJhTERT and U2OS cells, representing a telomerase-positive tumor cell line, a normal cell line, and an ALT tumor cell line, respectively. The gene discussed is GPT; the disease is neoplasm.